Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

July 23, 2015

Primary Completion Date

December 22, 2017

Study Completion Date

December 29, 2017

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

GSK3196165

GSK3196165 is supplied as liquid and will be administered as SC injection.

DRUG

MTX

MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.

DRUG

Folic acid

Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.

DRUG

Placebo

Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection

Trial Locations (64)

1

GSK Investigational Site, Pretoria

1036

GSK Investigational Site, Budapest

1431

GSK Investigational Site, Sofia

1606

GSK Investigational Site, Sofia

2143

GSK Investigational Site, Kistarcsa

4000

GSK Investigational Site, Plovdiv

4002

GSK Investigational Site, Plovdiv

7500

GSK Investigational Site, Panorama / Cape Town

7600

GSK Investigational Site, Stellenbosch

8200

GSK Investigational Site, Veszprém

10002

GSK Investigational Site, Zhytomyr

10117

GSK Investigational Site, Tallinn

13419

GSK Investigational Site, Tallinn

14059

GSK Investigational Site, Berlin

15006

GSK Investigational Site, A Coruña

18209

GSK Investigational Site, Bad Doberan

20132

GSK Investigational Site, Milan

21018

GSK Investigational Site, Vinnytsia

21029

GSK Investigational Site, Vinnytsia

28041

GSK Investigational Site, Madrid

36011

GSK Investigational Site, Poltava

40022

GSK Investigational Site, Sumy

40138

GSK Investigational Site, Bologna

44650

GSK Investigational Site, Guadalajara

50056

GSK Investigational Site, Kryvyi Rih

50937

GSK Investigational Site, Cologne

61029

GSK Investigational Site, Kharkiv

61039

GSK Investigational Site, Kharkiv

62170

GSK Investigational Site, Cuernavaca

62290

GSK Investigational Site, Cuernavaca

65026

GSK Investigational Site, Odesa

76008

GSK Investigational Site, Ivano-Frankivsk

78213

GSK Investigational Site, San Luis Potosí City

79013

GSK Investigational Site, Lviv

80131

GSK Investigational Site, Napoli

97000

GSK Investigational Site, Mérida

119049

GSK Investigational Site, Moscow

150003

GSK Investigational Site, Yaroslavl

150023

GSK Investigational Site, Yaroslavl

170036

GSK Investigational Site, Tver'

192177

GSK Investigational Site, Saint Petersburg

390026

GSK Investigational Site, Ryazan

600023

GSK Investigational Site, Vladimir

630099

GSK Investigational Site, Novosibirsk

644111

GSK Investigational Site, Omsk

L6T 0G1

GSK Investigational Site, Brampton

L4M 6L2

GSK Investigational Site, Barrie

602 00

GSK Investigational Site, Brno

792 01

GSK Investigational Site, Bruntál

130 00

GSK Investigational Site, Prague

150 06

GSK Investigational Site, Prague

686 01

GSK Investigational Site, Uherské Hradiště

D-20095

GSK Investigational Site, Hamburg

15-351

GSK Investigational Site, Bialystok

85-168

GSK Investigational Site, Bydgoszcz

41-902

GSK Investigational Site, Bytom

05-825

GSK Investigational Site, Grodzisk Mazowiecki

91-347

GSK Investigational Site, Lodz

20-582

GSK Investigational Site, Lublin

87-100

GSK Investigational Site, Torun

01-518

GSK Investigational Site, Warsaw

02-653

GSK Investigational Site, Warsaw

B15 2TH

GSK Investigational Site, Birmingham

LS7 4SA

GSK Investigational Site, Leeds

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02504671 - Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter